Key result
The treatment of heart failure with preserved ejection fraction associated with cardiac amyloidosis lacks specific evidence from randomized trials, requiring cautious use of traditional therapies to avoid hypotension and hypoperfusion.
Why the study?
The treatment of HFpEF associated with amyloidosis lacks specific evidence, and hypotension is a frequent concern during pharmacological management.
This review discusses strategies for managing HFpEF associated with cardiac amyloidosis, emphasizing the lack of specific evidence and the risk of hypotension with pharmacological treatment.
Cautious use of standard HF therapies remains warranted in amyloid HFpEF; leaves open the need for dedicated RCTs.
Heart failure with preserved ejection fraction (HFpEF) is a syndrome with multiple etiologies and varied phenotypic manifestations. Amyloidosis is a systemic disease that frequently affects the myocardium, and it may represent a specific etiology of HFpEF. The treatment of HFpEF associated with amyloidosis is not based on specific evidence, and the risk of hypotension as an adverse effect of pharmacological management is always a concern. In this context, this review addresses some strategies for controlling circulatory congestion, arrhythmias, cardiac [...]
No takes yet. Share an insight, caveat, or question.
Danzmann et al. (2021) conducted a review in Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis. The treatment of heart failure with preserved ejection fraction associated with cardiac amyloidosis lacks specific evidence from randomized trials, requiring cautious use of traditional therapies to avoid hypotension and hypoperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: